Listed

Traws Pharma, Inc.

TRAWNasdaqCIK 1130598HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025
Operating income−$3.2m, Q2 FY2026
Net income−$3.1m, Q2 FY2026
Traws Pharma, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.1Revenue, Q3 FY2023, three months to 2023-09-30$57.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure0.1Revenue, Q4 FY2023, three months to 2023-12-31$56.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001558370-25-004165. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2024, three months to 2024-03-31$56.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure0.1Revenue, Q2 FY2024, three months to 2024-06-30$57.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure0.1Revenue, Q3 FY2024, three months to 2024-09-30$57.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure0.1Revenue, Q4 FY2024, three months to 2024-12-31$56.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$57.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure2.7Revenue, Q2 FY2025, three months to 2025-06-30$2.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$m2.5Research and development, Q3 FY2023, three months to 2023-09-30$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure2.4Research and development, Q4 FY2023, three months to 2023-12-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2024-04-01, accession 0001558370-24-004525. Derived: 12-month figure less the 9-month figure.Report this figure1.9Research and development, Q1 FY2024, three months to 2024-03-31$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figurenot reportednot reportednot reported2.5Research and development, Q1 FY2025, three months to 2025-03-31$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure2.3Research and development, Q2 FY2025, three months to 2025-06-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figurenot reportednot reported4.9Research and development, Q1 FY2026, three months to 2026-03-31$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure1.1Research and development, Q2 FY2026, three months to 2026-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Operating income$m(5.1)Operating income, Q3 FY2023, three months to 2023-09-30−$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure(4.5)Operating income, Q4 FY2023, three months to 2023-12-31−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004165. Derived: 12-month figure less the 9-month figure.Report this figure(5.2)Operating income, Q1 FY2024, three months to 2024-03-31−$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure(123)Operating income, Q2 FY2024, three months to 2024-06-30−$123.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure(8.5)Operating income, Q3 FY2024, three months to 2024-09-30−$8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(5.3)Operating income, Q4 FY2024, three months to 2024-12-31−$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure(5.2)Operating income, Q1 FY2025, three months to 2025-03-31−$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(1.2)Operating income, Q2 FY2025, three months to 2025-06-30−$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure(4.1)Operating income, Q3 FY2025, three months to 2025-09-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(7.4)Operating income, Q4 FY2025, three months to 2025-12-31−$7.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure(6.9)Operating income, Q1 FY2026, three months to 2026-03-31−$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(3.2)Operating income, Q2 FY2026, three months to 2026-06-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(4.7)Net income, Q3 FY2023, three months to 2023-09-30−$4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure(4.2)Net income, Q4 FY2023, three months to 2023-12-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004165. Derived: 12-month figure less the 9-month figure.Report this figure(5.0)Net income, Q1 FY2024, three months to 2024-03-31−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure(123)Net income, Q2 FY2024, three months to 2024-06-30−$123.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure(8.5)Net income, Q3 FY2024, three months to 2024-09-30−$8.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(29.9)Net income, Q4 FY2024, three months to 2024-12-31−$29.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure21.5Net income, Q1 FY2025, three months to 2025-03-31$21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(0.9)Net income, Q2 FY2025, three months to 2025-06-30−$915.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure(4.0)Net income, Q3 FY2025, three months to 2025-09-30−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(7.4)Net income, Q4 FY2025, three months to 2025-12-31−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure(7.1)Net income, Q1 FY2026, three months to 2026-03-31−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(3.1)Net income, Q2 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Diluted EPS$ per share(5.64)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$5.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figurenot reported(5.92)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$5.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure(20.52)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$20.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure(1.49)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figurenot reported2.09Diluted EPS, Q1 FY2025, three months to 2025-03-31$2.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(0.11)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure(0.34)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figurenot reported(0.53)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(0.16)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Basic EPS$ per share(5.64)Basic EPS, Q3 FY2023, three months to 2023-09-30−$5.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figurenot reported(5.92)Basic EPS, Q1 FY2024, three months to 2024-03-31−$5.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure(20.52)Basic EPS, Q2 FY2024, three months to 2024-06-30−$20.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure(1.49)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figurenot reported2.17Basic EPS, Q1 FY2025, three months to 2025-03-31$2.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(0.11)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure(0.34)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figurenot reported(0.53)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(0.16)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure

Balance sheet

Cash and equivalents$20.6m, FY2023
Shareholders' equity$1.7m, Q2 FY2026
Traws Pharma, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported20.6Cash and equivalents, FY2023, at 2023-12-31$20.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2024-04-01, accession 0001558370-24-004525.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current assets$m27.0Current assets, Q3 FY2023, at 2023-09-30$27.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure22.7Current assets, FY2023, at 2023-12-31$22.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure18.2Current assets, Q1 FY2024, at 2024-03-31$18.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figure18.7Current assets, Q2 FY2024, at 2024-06-30$18.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-15, accession 0001558370-24-012279.Report this figure8.9Current assets, Q3 FY2024, at 2024-09-30$8.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure25.0Current assets, FY2024, at 2024-12-31$25.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure18.9Current assets, Q1 FY2025, at 2025-03-31$18.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure15.4Current assets, Q2 FY2025, at 2025-06-30$15.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure9.6Current assets, Q3 FY2025, at 2025-09-30$9.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure8.0Current assets, FY2025, at 2025-12-31$8.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure5.7Current assets, Q1 FY2026, at 2026-03-31$5.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure9.0Current assets, Q2 FY2026, at 2026-06-30$9.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Total assets$m27.0Total assets, Q3 FY2023, at 2023-09-30$27.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure22.7Total assets, FY2023, at 2023-12-31$22.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure18.2Total assets, Q1 FY2024, at 2024-03-31$18.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figure18.7Total assets, Q2 FY2024, at 2024-06-30$18.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-15, accession 0001558370-24-012279.Report this figure8.9Total assets, Q3 FY2024, at 2024-09-30$8.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure25.0Total assets, FY2024, at 2024-12-31$25.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure19.1Total assets, Q1 FY2025, at 2025-03-31$19.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure15.6Total assets, Q2 FY2025, at 2025-06-30$15.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure12.4Total assets, Q3 FY2025, at 2025-09-30$12.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure10.6Total assets, FY2025, at 2025-12-31$10.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure8.2Total assets, Q1 FY2026, at 2026-03-31$8.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure11.5Total assets, Q2 FY2026, at 2026-06-30$11.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Current liabilities$m9.7Current liabilities, Q3 FY2023, at 2023-09-30$9.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure9.2Current liabilities, FY2023, at 2023-12-31$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure9.4Current liabilities, Q1 FY2024, at 2024-03-31$9.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figure9.9Current liabilities, Q2 FY2024, at 2024-06-30$9.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-15, accession 0001558370-24-012279.Report this figure8.3Current liabilities, Q3 FY2024, at 2024-09-30$8.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure11.5Current liabilities, FY2024, at 2024-12-31$11.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure10.4Current liabilities, Q1 FY2025, at 2025-03-31$10.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure7.4Current liabilities, Q2 FY2025, at 2025-06-30$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure7.9Current liabilities, Q3 FY2025, at 2025-09-30$7.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure11.1Current liabilities, FY2025, at 2025-12-31$11.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure13.2Current liabilities, Q1 FY2026, at 2026-03-31$13.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure9.7Current liabilities, Q2 FY2026, at 2026-06-30$9.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Total liabilities$m12.5Total liabilities, Q3 FY2023, at 2023-09-30$12.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure12.0Total liabilities, FY2023, at 2023-12-31$12.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure12.2Total liabilities, Q1 FY2024, at 2024-03-31$12.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figure12.6Total liabilities, Q2 FY2024, at 2024-06-30$12.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-15, accession 0001558370-24-012279.Report this figure11.0Total liabilities, Q3 FY2024, at 2024-09-30$11.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure56.6Total liabilities, FY2024, at 2024-12-31$56.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure13.1Total liabilities, Q1 FY2025, at 2025-03-31$13.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure7.4Total liabilities, Q2 FY2025, at 2025-06-30$7.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure7.9Total liabilities, Q3 FY2025, at 2025-09-30$7.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure11.2Total liabilities, FY2025, at 2025-12-31$11.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure13.5Total liabilities, Q1 FY2026, at 2026-03-31$13.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure9.8Total liabilities, Q2 FY2026, at 2026-06-30$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure
Shareholders' equity$m14.5Shareholders' equity, Q3 FY2023, at 2023-09-30$14.5m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure10.7Shareholders' equity, FY2023, at 2023-12-31$10.7m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure6.0Shareholders' equity, Q1 FY2024, at 2024-03-31$6.0m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure(106)Shareholders' equity, Q2 FY2024, at 2024-06-30−$105.5m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(2.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$2.0m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(31.6)Shareholders' equity, FY2024, at 2024-12-31−$31.6m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure6.0Shareholders' equity, Q1 FY2025, at 2025-03-31$6.0m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure8.3Shareholders' equity, Q2 FY2025, at 2025-06-30$8.3m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure4.5Shareholders' equity, Q3 FY2025, at 2025-09-30$4.5m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure(0.6)Shareholders' equity, FY2025, at 2025-12-31−$629.0k. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure(5.3)Shareholders' equity, Q1 FY2026, at 2026-03-31−$5.3m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure1.7Shareholders' equity, Q2 FY2026, at 2026-06-30$1.7m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure

Cash flow

Operating cash flow−$7.5m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Traws Pharma, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(4.5)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001558370-24-015752. Derived: 9-month figure less the 6-month figure.Report this figure(4.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001558370-25-004165. Derived: 12-month figure less the 9-month figure.Report this figure(4.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure(9.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001558370-25-011469. Derived: 6-month figure less the 3-month figure.Report this figure(11.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$11.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure(4.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure(5.4)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(6.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097261. Derived: 6-month figure less the 3-month figure.Report this figure(4.0)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure(2.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure(2.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure(7.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097261. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reported0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001558370-25-004165. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reported0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)15.86m, Q2 FY2026
Traws Pharma, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares20.9Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3020,915,408 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001558370-23-019049.Report this figure21.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3120,960,171 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001558370-24-008326.Report this figure21.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3020,979,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-15, accession 0001558370-24-012279.Report this figure0.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30840,117 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure0.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31841,738 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0001558370-25-007872.Report this figure1.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,012,430 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001558370-25-011469.Report this figure1.0Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30961,530 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure7.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-317,215,125 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure5.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-305,820,903 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure8.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-308,818,859 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure10.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3110,640,625 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure15.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3015,864,041 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure

Shares outstanding: 15.37mShares outstanding, period not labelled, at 2026-08-1215,368,277 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.